US 11,719,697 B2
Immunoassay and antibodies for the detection of chromogranin A
Pascaline Caruhel, Nimes (FR); Valerie Rigault, Roquemaure (FR); and Nadine Guerin, Bagnols sur Ceze (FR)
Assigned to Cezanne S.A.S., Nimes (FR)
Filed by CEZANNE S.A.S., Nimes (FR)
Filed on Apr. 7, 2020, as Appl. No. 16/842,666.
Application 16/842,666 is a continuation of application No. 15/303,521, granted, now 10,648,984, previously published as PCT/EP2015/058045, filed on Apr. 14, 2015.
Claims priority of application No. 14164809 (EP), filed on Apr. 15, 2014.
Prior Publication US 2020/0348304 A1, Nov. 5, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); G01N 33/577 (2006.01); G01N 33/58 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01)
CPC G01N 33/5748 (2013.01) [C07K 16/18 (2013.01); C07K 16/30 (2013.01); G01N 33/577 (2013.01); G01N 33/582 (2013.01); C07K 2317/34 (2013.01)] 8 Claims
 
1. A method for the therapy control of a neuroendocrine tumour or prostate cancer in a subject comprising:
(a) determining the presence and/or absence or the level of Chromogranin A or a fragment thereof in a sample from said subject using an immunoassay method comprising the steps of:
(i) contacting said sample with a first antibody or an antigen-binding fragment thereof specific for Chromogranin A, and
(ii) a second antibody or an antigen-binding fragment thereof specific for Chromogranin A,
wherein the first antibody is produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231;
or the second antibody is produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232;
or the first antibody is produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 537/H2 deposited as DSM ACC3231, and the second antibody is produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232 or is an antigen-binding fragment of the antibody produced by the hybridoma cell line 541/E2 deposited as DSM ACC3232;
under conditions allowing for the formation of a ternary complex between Chromogranin A and the two antibodies or antigen-binding fragments or derivates thereof,
(c) detecting the binding of the two antibodies or antigen-binding fragments or derivates thereof to Chromogranin A;
(d) adjusting the therapeutic treatment of the subject.